Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT1 | Q99873 | 6/20 | 0.38 |
| ▸ | CARM1 | Q86X55 | 4/20 | 0.38 |
| ▸ | PRMT6 | Q96LA8 | 3/20 | 0.35 |
| ▸ | PRMT8 | Q9NR22 | 2/20 | 0.35 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | JAK1 | P23458 | 1/20 | 0.31 |
| ▸ | TYK2 | P29597 | 1/20 | 0.31 |
| ▸ | JAK3 | P52333 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16122002 | 0.89 | PRMT1 (0.50) | PRMT1CARM1PRMT6PRMT8PRMT3 | |
| SCHEMBL16187120 | 0.87 | HTR1D (0.39) | PRMT1CARM1PRMT6PRMT8PRMT3 | |
| SCHEMBL17467649 | 0.86 | PRMT1 (0.52) | PRMT1CARM1PRMT6PRMT8PRMT3 | |
| SCHEMBL16187107 | 0.85 | HTR1D (0.39) | PRMT1CARM1PRMT6PRMT8PRMT3 | |
| SCHEMBL16187103 | 0.84 | HTR1D (0.30) | PRMT1CARM1PRMT6PRMT8PRMT3 | |
| SCHEMBL16187121 | 0.80 | PRMT1 (0.36) | PRMT1CARM1PRMT6PRMT8PRMT3 | |
| SCHEMBL16187080 | 0.77 | CARM1 (0.41) | PRMT1CARM1PRMT6PRMT8PRMT3 | |
| SCHEMBL17470704 | 0.77 | PRMT1 (0.47) | PRMT1CARM1PRMT6PRMT8PRMT3 | |
| SCHEMBL17467642 | 0.77 | PRMT1 (0.38) | PRMT1CARM1PRMT6PRMT8PRMT3 | |
| SCHEMBL19449948 | 0.76 | PRMT1 (0.52) | PRMT1CARM1PRMT6PRMT8PRMT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9724332-B2 | Arginine methyltransferase inhibitors and uses thereof | Epizyme, Inc. (US) | 2017-08-08 | — | — | US | disclosed |
| US-20160184267-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. | 2016-06-30 | — | — | US | disclosed |
| US-9120757-B2 | Arginine methyltransferase inhibitors and uses thereof | Epizyme, Inc. (US) | 2015-09-01 | — | — | US | disclosed |
| US-20140315904-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315904-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | PRMT1 1/4885CARM1 11/4885PRMT6 4/4885 |
| US-20160184267-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | PRMT1 1/4885CARM1 11/4885PRMT6 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.